Skip to main content
. 2019 May 11;9(5):96. doi: 10.3390/metabo9050096

Figure 4.

Figure 4

Distribution of GTP-related urine metabolites in 4 treatment groups. (A) Relative abundance of 5-(dihydroxyphenyl)-γ-valerolactone sulfate (Iu). (B) Relative abundance of 5-(dihydroxyphenyl)-γ-valerolactone sulfate (IIu). (C) Relative abundance of 5-(dihydroxyphenyl)-γ-valerolactone glucuronide (IIIu). (D) Relative abundance of methyl epicatechin sulfate (IVu). (E) Relative abundance of methyl epigallocatechin glucuronide (Vu). (F) Concentration of phenylacetylglutamine (VIu). (G) Concentration of hippuric acid (VIIu). (H) Concentration of indoxyl sulfate (VIIIu). (Labels a and b indicate whether statistical difference (p < 0.05) between 2 sample groups from one-way ANOVA and Tukey’s multiple comparison tests.).